[
  {
    "ts": null,
    "headline": "Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries",
    "summary": "FOSTER CITY, Calif., September 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead’s larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fu",
    "url": "https://finnhub.io/api/news?id=ccf7a16c70035c57d88d6887ed37370234bb9bb4e914ae9b083a961fdc7edfdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757013300,
      "headline": "Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries",
      "id": 136642162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., September 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead’s larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fu",
      "url": "https://finnhub.io/api/news?id=ccf7a16c70035c57d88d6887ed37370234bb9bb4e914ae9b083a961fdc7edfdd"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757007155,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 136639750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
      "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3"
    }
  },
  {
    "ts": null,
    "headline": "Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer",
    "summary": "The Australia Acute Respiratory Distress Syndrome (ARDS) Market is forecasted to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, with a CAGR of 6.78%. Key drivers include a rising incidence of respiratory diseases, ICU admissions, and technological innovations. Growing awareness of post-COVID lung damage and an aging population further propel demand. Diagnostic and treatment advancements, such as the VitalFlow ECMO System by Medtronic, enhance patient outcomes. Government inves",
    "url": "https://finnhub.io/api/news?id=0124393ccb36eeb8291d3e6b7bd4f6272f11f4b748de403052e6727dbb81deb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757001600,
      "headline": "Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer",
      "id": 136642156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Australia Acute Respiratory Distress Syndrome (ARDS) Market is forecasted to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, with a CAGR of 6.78%. Key drivers include a rising incidence of respiratory diseases, ICU admissions, and technological innovations. Growing awareness of post-COVID lung damage and an aging population further propel demand. Diagnostic and treatment advancements, such as the VitalFlow ECMO System by Medtronic, enhance patient outcomes. Government inves",
      "url": "https://finnhub.io/api/news?id=0124393ccb36eeb8291d3e6b7bd4f6272f11f4b748de403052e6727dbb81deb3"
    }
  },
  {
    "ts": null,
    "headline": "Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva",
    "summary": "The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from $1.32 billion in 2024 to $2.53 billion by 2033, registering a CAGR of 7.51% from 2025 to 2033. Key factors driving this growth include the rise in chronic respiratory diseases, advancements in oxygen therapy and mechanical ventilation, and increased awareness for early diagnosis and individualized care. Imaging and clinical criteria are vital for ARDS diagnosis, with new medical technologies and heightened healthcare",
    "url": "https://finnhub.io/api/news?id=b63f87c4c0409874ef2bd98794433ccd2cb8aacf1caa2d4bdc4ef8c7436506ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757000760,
      "headline": "Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva",
      "id": 136642165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from $1.32 billion in 2024 to $2.53 billion by 2033, registering a CAGR of 7.51% from 2025 to 2033. Key factors driving this growth include the rise in chronic respiratory diseases, advancements in oxygen therapy and mechanical ventilation, and increased awareness for early diagnosis and individualized care. Imaging and clinical criteria are vital for ARDS diagnosis, with new medical technologies and heightened healthcare",
      "url": "https://finnhub.io/api/news?id=b63f87c4c0409874ef2bd98794433ccd2cb8aacf1caa2d4bdc4ef8c7436506ed"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
    "summary": "Gilead Sciences highlights strong growth, successful Yeztugo HIV prevention launch, and",
    "url": "https://finnhub.io/api/news?id=171bc9215484b0c1a19526592c5962d4ef3490b6a37244ce269b77890fb2a042",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756994432,
      "headline": "Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
      "id": 136638405,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences highlights strong growth, successful Yeztugo HIV prevention launch, and",
      "url": "https://finnhub.io/api/news?id=171bc9215484b0c1a19526592c5962d4ef3490b6a37244ce269b77890fb2a042"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV",
    "summary": "FOSTER CITY, Calif., September 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign launch coincides with the convening of the 2025 United States Conference on HIV/AIDS (USCHA) taking place September 4-7 in Washington DC, which will center on the theme of aging with HIV.",
    "url": "https://finnhub.io/api/news?id=8867a5474a636228ca22bde8fcf47b44af6b2691c5bc54365cf9200333e51e7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756992600,
      "headline": "Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV",
      "id": 136642166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., September 04, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HIV globally. The timing of the campaign launch coincides with the convening of the 2025 United States Conference on HIV/AIDS (USCHA) taking place September 4-7 in Washington DC, which will center on the theme of aging with HIV.",
      "url": "https://finnhub.io/api/news?id=8867a5474a636228ca22bde8fcf47b44af6b2691c5bc54365cf9200333e51e7c"
    }
  },
  {
    "ts": null,
    "headline": "IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer",
    "summary": "IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors. IDEAY",
    "url": "https://finnhub.io/api/news?id=e24c79564cb07cdfc5132ffa6dac07dbb0501651bde719d8a0e71e0b47be793b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756983600,
      "headline": "IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer",
      "id": 136642167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCLC) in the ongoing Phase 1/2 combination trial of IDE397, a potential first-in-class, small molecule adenosyltransferase 2a (MAT2a) inhibitor, and Trodelvy® (sacituzumab govitecan-hziy), a Trop2-directed antibody-drug conjugate (ADC), in patients with methylthioadenosine phosphorylase (MTAP)-deletion solid tumors. IDEAY",
      "url": "https://finnhub.io/api/news?id=e24c79564cb07cdfc5132ffa6dac07dbb0501651bde719d8a0e71e0b47be793b"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences Stock Underperforming the Nasdaq?",
    "summary": "Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=3ade1acbea62e943191d758c5d939ed16dc93ae308905cbae09798570d41d209",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756972638,
      "headline": "Is Gilead Sciences Stock Underperforming the Nasdaq?",
      "id": 136642168,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=3ade1acbea62e943191d758c5d939ed16dc93ae308905cbae09798570d41d209"
    }
  }
]